Effects of lurasidone on executive function in common marmosets

Behavioural Brain Research

Volumn 246, Issue , 2013, Pages 125-131

  Murai, Takeshi ^a   Nakako, Tomokazu ^a   Ikejiri, Masaru ^a   Ishiyama, Takeo ^a   Taiji, Mutsuo ^a   Ikeda, Kazuhito ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Antipsychotics; Cognition; Common marmoset; Lurasidone; Object retrieval with detour; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; LURASIDONE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AGE; ANIMAL EXPERIMENT; ARTICLE; CALLITRICHINAE; CONTROLLED STUDY; DOSE RESPONSE; DROWSINESS; DRUG EFFECT; DRUG MEGADOSE; EXECUTIVE FUNCTION; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; SEDATION; SEX DIFFERENCE; TASK PERFORMANCE; VOMITING;

ANIMALS; ANTIPSYCHOTIC AGENTS; CALLITHRIX; DOSE-RESPONSE RELATIONSHIP, DRUG; EXECUTIVE FUNCTION; EXPLORATORY BEHAVIOR; FEMALE; ISOINDOLES; MALE; SPATIAL BEHAVIOR; THIAZOLES; TIME FACTORS;

EID: 84875684848     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.02.019     Document Type: Article

References (38)

1. Tandon R., Keshavan M.S., Nasrallah H.A. Schizophrenia, just the facts what we know in 2008. 2. Epidemiology and etiology. Schizophrenia Research 2008, 102:1-18.
2. Green M.F., Nuechterlein K.H., Gold J.M., Barch D.M., Cohen J., Essock S., et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry 2004, 56:301-307.
3. Harvey P.D., Green M.F., Keefe R.S., Velligan D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. Journal of Clinical Psychiatry 2004, 65:361-372.
4. Sharma T., Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatric Clinics of North America 2003, 26:25-40.
5. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophrenia Research 2004, 72:29-39.
6. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the right stuff. Schizophrenia Bulletin 2000, 26:119-136.
7. Wu J.C., Buchsbaum M.S., Bunney W.E. Positron emission tomography study of phencyclidine users as a possible drug model of schizophrenia. Yakubutsu, Seishin, Kodo 1991, 11:47-48.
8. Brown V.J., Bowman E.M. Rodent models of prefrontal cortical function. Trends in Neurosciences 2002, 25:340-343.
9. Uylings H.B., Groenewegen H.J., Kolb B. Do rats have a prefrontal cortex. Behavioural Brain Research 2003, 146:3-17.
10. Diamond A., Zola-Morgan S., Squire L.R. Successful performance by monkeys with lesions of the hippocampal formation on AB and object retrieval, two tasks that mark developmental changes in human infants. Behavioral Neuroscience 1989, 103:526-537.
11. Wilkinson L.S., Dias R., Thomas K.L., Augood S.J., Everitt B.J., Robbins T.W., et al. Contrasting effects of excitotoxic lesions of the prefrontal cortex on the behavioural response to d-amphetamine and presynaptic and postsynaptic measures of striatal dopamine function in monkeys. Neuroscience 1997, 80:717-730.
12. Wallis J.D., Dias R., Robbins T.W., Roberts A.C. Dissociable contributions of the orbitofrontal and lateral prefrontal cortex of the marmoset to performance on a detour reaching task. European Journal of Neuroscience 2001, 13:1797-1808.
13. Jentsch J.D., Redmond D.E., Elsworth J.D., Taylor J.R., Youngren K.D., Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 1997, 277:953-955.
14. Jentsch J.D., Taylor J.R., Redmond D.E., Elsworth J.D., Youngren K.D., Roth R.H. Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys. Psychopharmacology 1999, 142:78-84.
15. Rutten K., Basile J.L., Prickaerts J., Blokland A., Vivian J.A. Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques. Psychopharmacology 2008, 196:643-648.
16. Ballard T.M., Knoflach F., Prinssen E., Borroni E., Vivian J.A., Basile J., et al. RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors. Psychopharmacology 2009, 202:207-223.
17. Newman J.D., Kenkel W.M., Aronoff E.C., Bock N.A., Zametkin M.R., Silva A.C. A combined histological and MRI brain atlas of the common marmoset monkey, Callithrix jacchus. Brain Research Reviews 2009, 62:1-18.
18. Sasaki E., Suemizu H., Shimada A., Hanazawa K., Oiwa R., Kamioka M., et al. Generation of transgenic non-human primates with germline transmission. Nature 2009, 459:523-527.
19. Schatten G., Mitalipov S. Developmental biology: transgenic primate offspring. Nature 2009, 459:515-516.
20. Cagni P., Gonçalves I., Ziller F., Emile N., Barros M. Humans and natural predators induce different fear/anxiety reactions and response pattern to diazepam in marmoset monkeys. Pharmacology Biochemistry and Behavior 2009, 93:134-140.
21. Ishibashi T., Horisawa T., Tokuda K., Ishiyama T., Ogasa M., Tagashira R., et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. Journal of Pharmacology and Experimental Therapeutics 2010, 334:171-181.
22. Ishiyama T., Tokuda K., Ishibashi T., Ito A., Toma S., Ohno Y. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. European Journal of Pharmacology 2007, 572:160-170.
23. Enomoto T., Ishibashi T., Tokuda K., Ishiyama T., Toma S., Ito A. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behavioural Brain Research 2008, 186:197-207.
24. Horiguchi M., Huang M., Meltzer H.Y. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. Journal of Pharmacology and Experimental Therapeutics 2011, 338:605-614.
25. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. International Journal of Clinical Practice 2011, 65:189-210.
26. Diamond A. Developmental time course in human infants and infant monkeys, and the neural bases of, inhibitory control in reaching. Annals of the New York Academy of Sciences 1990, 608:637-676.
27. Man M.S., Clarke H.F., Roberts A.C. The role of the orbitofrontal cortex and medial striatum in the regulation of prepotent responses to food rewards. Cerebral Cortex 2009, 19:899-906.
28. Roberts A.C., Tomic D.L., Parkinson C.H., Roeling T.A., Cutter D.J., Robbins T.W., et al. Forebrain connectivity of the prefrontal cortex in the marmoset monkey (Callithrix jacchus): an anterograde and retrograde tract-tracing study. Journal of Comparative Neurology 2007, 502:86-112.
29. Grass H., Klotz T., Fathian-Sabet B., Berghaus G., Engelmann U., Kaferstein H. Sildenafil (Viagra): is there an influence on psychological performance?. International Urology and Nephrology 2001, 32:409-412.
30. Schultheiss D., Muller S.V., Nager W., Stief C.G., Schlote N., Jonas U., et al. Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials. World Journal of Urology 2001, 19:46-50.
31. Tinsley M.R., Basile J.L., Van-Natta K., Yeo H. Cognition enhancing effects of nicotinic acetylcholine alpha-7 receptor agonists in prefrontal cortex mediated tasks in adult monkeys. 37th Annu Meet Soc Neurosci 2007, [Abst 746.3].
32. 2A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography. Psychopharmacology 2013, 225:329-339.
33. Horisawa T., Ishibashi T., Nishikawa H., Enomoto T., Toma S., Ishiyama T., et al. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behavioural Brain Research 2011, 220:83-906.
34. Puig M.V., Gulledge A.T. Serotonin and prefrontal cortex function: neurons, networks, and circuits. Molecular Neurobiology 2011, 44:449-464.
35. Walker S.C., Mikheenko Y.P., Argyle L.D., Robbins T.W., Roberts A.C. Selective prefrontal serotonin depletion impairs acquisition of a detour-reaching task. European Journal of Neuroscience 2006, 23:3119-3123.
36. Kamei C., Chung Y.H., Tasaka K. Influence of certain H1-blockers on the step-through active avoidance response in rats. Psychopharmacology 1990, 102(3):312-318.
37. Mori K., Yamashita H., Nagao M., Horiguchi J., Yamawaki S. Effects of anticholinergic drug withdrawal on memory, regional cerebral blood flow and extrapyramidal side effects in schizophrenic patients. Pharmacopsychiatry 2002, 35(1):6-11.
38. Krystal J.H., D'Souza D.C., Mathalon D., Perry E., Belger A., Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 2003, 169:215-233.